Roivant Sciences (ROIV) Competitors

BioNTech (NASDAQ:BNTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Does the MarketBeat Community believe in BNTX or ROIV?

BioNTech received 90 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 46.93% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 145 46.93%	Underperform Votes 164 53.07%
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%

Which has higher valuation and earnings, BNTX or ROIV?

Roivant Sciences has lower revenue, but higher earnings than BioNTech. Roivant Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	10.03	$1.01B	-$3.00	-38.32
Roivant Sciences	$122.59M	62.52	$4.35B	-$0.15	-71.60

Which has more risk and volatility, BNTX or ROIV?

BioNTech has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Do analysts recommend BNTX or ROIV?

BioNTech presently has a consensus price target of $143.44, suggesting a potential upside of 24.76%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 62.94%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is BNTX or ROIV more profitable?

BioNTech has a net margin of -15.16% compared to Roivant Sciences' net margin of -119.54%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Roivant Sciences	-119.54%	-14.05%	-12.81%

Does the media favor BNTX or ROIV?

In the previous week, Roivant Sciences had 1 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Roivant Sciences and 17 mentions for BioNTech. BioNTech's average media sentiment score of 1.03 beat Roivant Sciences' score of 0.65 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in BNTX or ROIV?

15.5% of BioNTech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioNTech and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks.